Yuping Li Selected Research

Purinergic P2X3 Receptors

12/2021	Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial.
1/2020	Gefapixant in two randomised dose-escalation studies in chronic cough.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuping Li Research Topics

Disease

34	Neoplasms (Cancer) 05/2024 - 01/2005
13	Infections 05/2024 - 01/2013
13	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2023 - 01/2016
10	Pneumonia (Pneumonitis) 11/2023 - 01/2016
8	Inflammation (Inflammations) 07/2023 - 01/2014
8	Acute Lung Injury 01/2023 - 08/2011
7	Lung Neoplasms (Lung Cancer) 11/2023 - 09/2015
7	Neoplasm Metastasis (Metastasis) 01/2023 - 12/2007
7	Chronic Obstructive Pulmonary Disease (COPD) 02/2021 - 01/2014
6	Adenocarcinoma of Lung 01/2022 - 01/2008
5	Ischemic Stroke 03/2024 - 01/2019
5	Brain Neoplasms (Brain Tumor) 11/2023 - 11/2021
5	Glioblastoma (Glioblastoma Multiforme) 01/2023 - 08/2014
5	Traumatic Brain Injuries (Traumatic Brain Injury) 06/2022 - 01/2014
5	Glioma (Gliomas) 01/2022 - 08/2014
4	Sepsis (Septicemia) 05/2024 - 10/2022
4	Pulmonary Hypertension 01/2023 - 02/2014
4	Disease Progression 11/2022 - 01/2021
4	Lung Injury 02/2022 - 08/2011
4	Hypoxia (Hypoxemia) 01/2022 - 06/2010
4	Hematoma 02/2020 - 12/2018
3	Pain (Aches) 04/2024 - 04/2022
3	Hypertension (High Blood Pressure) 11/2023 - 02/2014
3	Human Influenza (Influenza) 11/2023 - 06/2008
3	Primary Graft Dysfunction 01/2023 - 01/2022
3	Obesity 03/2022 - 09/2009
3	Neuralgia (Stump Neuralgia) 01/2022 - 11/2017
3	Cognitive Dysfunction 07/2021 - 10/2016
3	COVID-19 02/2021 - 01/2020
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 05/2012 - 11/2002
2	Dehydration (Water Stress) 12/2023 - 10/2020
2	Epilepsy (Aura) 02/2023 - 02/2023
2	Urinary Tract Infections (Urinary Tract Infection) 02/2023 - 02/2023
2	Idiopathic Pulmonary Fibrosis 01/2023 - 12/2021
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2023 - 09/2019
2	Hyperalgesia 11/2022 - 01/2022
2	Wounds and Injuries (Trauma) 04/2022 - 10/2016
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 03/2022 - 01/2022
2	Pathologic Constriction (Stenosis) 01/2022 - 01/2022
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2021
2	Chronic Cough 12/2021 - 01/2020

Drug/Important Bio-Agent (IBA)

16	Proteins (Proteins, Gene)FDA Link 05/2024 - 01/2008
16	Biomarkers (Surrogate Marker)IBA 03/2024 - 01/2012
7	ErbB Receptors (EGF Receptor)IBA 04/2022 - 01/2016
6	MicroRNAs (MicroRNA)IBA 12/2022 - 01/2012
6	LipopolysaccharidesIBA 06/2022 - 01/2014
5	Anti-Bacterial Agents (Antibiotics)IBA 05/2024 - 06/2019
5	DNA (Deoxyribonucleic Acid)IBA 02/2023 - 01/2017
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2023 - 10/2016
5	Gefitinib (Iressa)FDA Link 11/2022 - 08/2017
5	Tyrosine Kinase InhibitorsIBA 11/2022 - 01/2016
5	Therapeutic UsesIBA 06/2022 - 08/2011
5	Neuroprotective AgentsIBA 05/2020 - 10/2016
5	SmokeIBA 01/2020 - 01/2014
4	Immune Checkpoint InhibitorsIBA 12/2023 - 03/2021
4	Glucose (Dextrose)FDA LinkGeneric 03/2022 - 01/2021
4	EnzymesIBA 02/2022 - 01/2005
4	Oxygen (Dioxygen)IBA 01/2022 - 12/2007
4	CytokinesIBA 01/2021 - 01/2016
3	IronIBA 05/2024 - 10/2016
3	Long Noncoding RNAIBA 05/2024 - 01/2021
3	PlatinumIBA 11/2023 - 01/2021
3	AlbuminsIBA 11/2023 - 02/2023
3	Prostaglandins DIBA 01/2023 - 01/2022
3	ProcalcitoninIBA 10/2022 - 06/2019
3	Interleukin-6 (Interleukin 6)IBA 10/2022 - 01/2016
3	Circulating Tumor DNAIBA 04/2022 - 01/2017
3	AntioxidantsIBA 01/2022 - 01/2005
3	Connexin 43 (Connexin43)IBA 01/2022 - 01/2018
3	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 05/2020 - 01/2005
3	AlloxanIBA 05/2012 - 11/2002
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2008 - 01/2005
2	Xanthine OxidaseIBA 02/2024 - 01/2023
2	Nanoparticle Drug Delivery SystemIBA 01/2023 - 01/2022
2	Dexmedetomidine FDA Link 11/2022 - 01/2022
2	aflutinibIBA 11/2022 - 11/2022
2	Interleukin-10 (Interleukin 10)IBA 10/2022 - 07/2021
2	LipidsIBA 03/2022 - 09/2009
2	RNA (Ribonucleic Acid)IBA 03/2022 - 01/2018
2	Liposomes (Liposome)IBA 01/2022 - 10/2021
2	Small Interfering RNA (siRNA)IBA 01/2022 - 10/2021
2	SiliconesIBA 01/2022 - 03/2018
2	AfatinibIBA 01/2022 - 10/2021
2	CateninsIBA 01/2022 - 01/2022
2	Sincalide FDA Link 01/2022 - 07/2015
2	pyrotinibIBA 01/2022 - 01/2022
2	GefapixantIBA 12/2021 - 01/2020
2	Purinergic P2X3 ReceptorsIBA 12/2021 - 01/2020

Therapy/Procedure

24	Therapeutics 11/2022 - 08/2011
8	Drug Therapy (Chemotherapy) 11/2023 - 08/2017
5	Length of Stay 02/2023 - 01/2016
3	Punctures 05/2024 - 04/2022
3	Immunotherapy 11/2023 - 01/2022
3	Craniotomy 11/2023 - 06/2019
3	Catheters 02/2023 - 01/2020
3	Transplantation 11/2022 - 11/2017
3	Stents 01/2022 - 03/2018
2	Ligation 05/2024 - 07/2023
2	Critical Care (Surgical Intensive Care) 02/2023 - 02/2023
2	Laminectomy 02/2022 - 01/2019